SEC Tracker
Get the app

Jupiter Neurosciences JUNS

Jupiter Neurosciences FY 2024: net loss $2.4M; diluted EPS −$0.08

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Jupiter Neurosciences reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$2.4MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$0.08No year-earlier figure tagged10-K income statement, on EDGAR
  3. Cash and cash equivalents$3.8MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  4. Cash from operations−$3.9MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Jupiter Neurosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Fibrogen FGEN public float $21M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. Imunon IMNN public float $21M, Jun 30, 2025
  4. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  5. Dare Bioscience DARE public float $21M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.